Vaginal Estrogen for Perimenopause and Menopause

Why It's Safe, Effective, and Underused

Vaginal estrogen is one of the most effective — and most misunderstood — treatments in women's health. It has decades of clinical evidence behind it, strong support from every major medical organization, and an excellent safety profile. And yet, the majority of women who could benefit from it never receive it.

Too many women are told to "just live with it" when they experience vaginal dryness, irritation, pain during sex, or recurrent urinary tract infections after menopause. They shouldn't have to — and they don't have to.

What Is Vaginal Estrogen and What Does It Treat?

Vaginal estrogen is a low-dose form of estrogen applied directly to the vaginal tissue, typically as a cream, tablet, insert, or ring. Unlike systemic hormone therapy (pills or patches that circulate estrogen throughout the body), vaginal estrogen works locally — restoring moisture, thickness, and elasticity to the vaginal and urethral tissue with very little absorption into the bloodstream.

During menopause, declining estrogen levels cause significant changes to the vaginal and urinary tract. The medical term for this is genitourinary syndrome of menopause (GSM), and it affects an estimated 27% to 84% of postmenopausal women. Unlike hot flashes, which tend to improve over time, GSM symptoms typically worsen with age if left untreated.

Low-dose vaginal estrogen is effective for treating vaginal dryness, one of the most common and bothersome menopause symptoms. It relieves burning, irritation, and itching of the vulva and vaginal tissue. It significantly reduces pain during intercourse (dyspareunia), which affects sexual health and quality of life for millions of women. It helps prevent recurrent urinary tract infections by restoring healthy vaginal pH and supporting the growth of protective bacteria. And it addresses tissue changes that can occur after menopause, childbirth, breastfeeding, or certain cancer treatments.

Vaginal estrogen is considered a first-line prescription treatment for moderate to severe GSM by the North American Menopause Society (NAMS), the American Urological Association (AUA), and other leading medical organizations.

The Biggest Myth About Vaginal Estrogen: "Estrogen Is Dangerous"

This is the single biggest barrier to treatment — and it's based on a misunderstanding.

Much of the fear around estrogen stems from the 2002 Women's Health Initiative (WHI) study, which found increased risks of certain conditions in women taking systemic hormone therapy (oral estrogen plus progestin). That study changed the conversation around menopause treatment dramatically, and while it provided important data about systemic HRT, the findings were broadly — and often inaccurately — applied to all forms of estrogen, including low-dose vaginal formulations.

Here's what the current evidence actually shows. Low-dose vaginal estrogen has minimal systemic absorption. The amount of estrogen that reaches the bloodstream is far lower than what circulates during a normal menstrual cycle — typically staying within the normal postmenopausal range. Vaginal estrogen does not carry the same risk profile as systemic hormone therapy. Long-term follow-up from the Nurses' Health Study found no association between vaginal estrogen use and increased risk of cardiovascular disease, breast cancer, endometrial cancer, ovarian cancer, or hip fracture.

It is considered safe for most women, including many who cannot take oral estrogen. Major medical guidelines, including the 2025 AUA/SUFU/AUGS guideline on GSM, strongly recommend offering low-dose vaginal estrogen to symptomatic patients. And in a landmark regulatory development, the FDA recently removed the black box warning from vaginal estrogen products — the warning that had been carried over from systemic hormone therapy data and had contributed to decades of under-prescribing.

A progestogen is generally not required for endometrial protection when using low-dose vaginal estrogen, according to both NAMS and the AUA guidelines. This further simplifies treatment.

Why Vaginal Estrogen Is So Underused

If vaginal estrogen is this effective and this safe, why aren't more women receiving it? The answer is a combination of systemic factors that have nothing to do with the medication itself.

Lack of education is a major driver. Many women don't know that GSM is a medical condition with effective treatments — they assume vaginal dryness and discomfort are just an inevitable part of aging. Even many healthcare providers receive limited training on menopause management, particularly around vaginal and sexual health.

Overestimation of risk persists despite the evidence. The legacy of the WHI study continues to create hesitancy among both patients and clinicians, even though the data on low-dose vaginal estrogen tells a very different story from systemic HRT. The removal of the FDA black box warning is an important step, but changing deeply held perceptions takes time.

Discomfort discussing sexual health plays a significant role. Vaginal dryness and painful intercourse are deeply personal topics, and many women are reluctant to bring them up — especially if their provider doesn't ask. Research shows that fewer than half of women with GSM symptoms seek medical attention or are offered help by their providers.

Short office visits that prioritize other concerns mean that menopause symptoms, particularly those affecting sexual and vaginal health, often get pushed to the bottom of the list — or left off entirely.

The result is that millions of women are living with treatable symptoms, often for years, without knowing that a safe and effective option exists.

What to Expect When Starting Vaginal Estrogen

Vaginal estrogen is available in several forms, and the right choice depends on your symptoms, preferences, and lifestyle. Options include vaginal estrogen cream (such as Estrace or Premarin), which is applied with an applicator, typically daily for the first 1–3 weeks and then 2–3 times per week. Vaginal estrogen tablets or inserts (such as Vagifem or Imvexxy) are small tablets or softgel inserts placed in the vagina, usually daily for two weeks and then twice weekly. And the vaginal estrogen ring (such as Estring) is a small, flexible ring inserted in the vagina that releases a low, steady dose of estrogen for three months at a time.

All of these formulations are considered equally effective. Your provider can help you determine which option fits best for you.

Most women begin to notice improvement in dryness and comfort within 2–4 weeks of starting treatment. Fuller benefits — including improvements in tissue health, reduction in UTIs, and relief from painful intercourse — typically develop over 6–12 weeks. Some women experience mild burning or breast tenderness in the first few weeks, which usually resolves as the tissue begins to heal.

It's important to understand that GSM is a chronic condition. Symptoms tend to return if treatment is stopped, so most women benefit from ongoing, long-term use. The good news is that the safety profile supports long-term treatment, and vaginal estrogen is one of the highest-satisfaction therapies in medicine — once women start it, the vast majority are glad they did.

The DefineMD Approach

At DefineMD, we treat vaginal health as a priority — not an afterthought. We understand that these symptoms can be difficult to talk about, and we're here to make that conversation easier.

Our approach starts with listening. We take the time to understand your symptoms, your health history, and your goals. We prescribe evidence-based vaginal estrogen therapy when appropriate, choosing the right formulation for your needs. We provide clear guidance on how to use it, what to expect, and when to follow up. And we're available for ongoing support as your body adjusts and your needs evolve.

You don't have to live with vaginal dryness, painful sex, or recurrent UTIs. These are treatable conditions, and you deserve care that takes them seriously.

Ready to talk about treatment options? Schedule a consultation with DefineMD — with compassion, understanding, and evidence-based care.